Allarity shares surge 16.97% after-hours as VA-funded Phase 2 trial for relapsed SCLC begins dosing patients with stenoparib-temozolomide combo.

Allarity Therapeutics surged 16.97% in after-hours trading following the announcement that it dosed first patients in a VA-funded Phase 2 trial evaluating stenoparib plus temozolomide for relapsed small cell lung cancer. The trial, fully funded by the U.S. Department of Veterans Affairs and enrolling at 11 VA medical centers, highlights stenoparib’s dual PARP and WNT pathway inhibition, which the company claims may enhance temozolomide efficacy and address drug resistance. Additionally, favorable tolerability compared to earlier PARP inhibitors is cited as a potential advantage for sustained combination therapy. The trial’s initiation represents a key milestone for the company’s pipeline, likely driving investor optimism.